Addressing Unmet Needs in First-Line Treatment for Elderly DLBCL and Roche's Unique Portfolio Integration

Previously, elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) often found it difficult to fully adhere to the standard R-CHOP regimen due to concerns about side effects. Alternative regimens, such as R-miniCHOP, which reduce or eliminate vincristine (a neurotoxic agent), were commonly used. However, these alternatives showed significantly lower complete response rates (CRR) compared to younger patients. To overcome this limitation, Memorial Sloan Kettering Cancer Center (MSKCC) and Roche (RHHBY), through its subsidiary Genentech, are leveraging their oncology portfolio. The approach involves pretreating patients with obinutuzumab (a CD20-targeting monoclonal antibody) to reduce tumor burden, followed by a combination of glofitamab (a bispecific antibody targeting CD20 and CD3) and polatuzumab vedotin (an antibody-drug conjugate targeting CD79b) in conjunction with a reduced-dose R-miniCHP chemotherapy regimen.

GLORY Phase 2 Trial: A Refined Treatment Regimen and Response-Adaptive Design

The Phase 2 GLORY trial (NCT06765317), which commenced on January 16, 2025, is actively recruiting patients and aims for a completion date of January 2028. This study goes beyond simply combining multiple drugs; it employs a response-adaptive design, adjusting the duration of drug administration based on the patient's early treatment response. All patients will undergo a two-cycle treatment with glofitamab and polatuzumab vedotin, followed by an interim PET scan. If complete response is achieved, only a total of four cycles of the combination therapy will be administered. If the patient exhibits partial response or stable disease, the treatment will be extended to six cycles, aiming to maximize efficacy while minimizing the physical burden on elderly patients.

Roche's Strategy to Secure a Leading Position in the Bispecific Antibody Market and Gain a Competitive Advantage

Roche's glofitamab has achieved significant growth, with sales reaching approximately USD 188 million in 2024, after receiving FDA accelerated approval as a 'third-line treatment' in June 2023. However, with the emergence of epcoritamab (a bispecific antibody from AbbVie and Genmab) as a strong competitor, proactively expanding the indication to first-line treatment ('Frontline') is crucial. If this trial, combining polatuzumab vedotin and glofitamab, which is already approved for first-line use, proves successful, Roche will be able to offer a unique combination therapy option for elderly and frail DLBCL patients in the first-line setting. This strategy not only accelerates market entry compared to competitors but also strengthens the barriers to entry through synergy between its own drugs.

Impact on the Hematological Malignancy Market and Investment Outlook

The global DLBCL treatment market is estimated at approximately USD 5.7 billion in 2025 and is projected to grow to USD 9.94 billion by 2033, with an annual growth rate of 7.5%. The elderly patient population, including those aged 65 and over and 80 and over, who are the target of this trial, is expected to continue to increase as societies age. If the combination therapy of polatuzumab vedotin and glofitamab, which recorded year-on-year sales growth of over 30% in 2025, demonstrates excellent safety and complete response rates in elderly patients in the first-line setting, Roche's hematological malignancy franchise could achieve further quantum leaps. From the perspective of venture capital (VC) and biotech investors, the interim data and the potential for accelerated approval to be announced by January 2028, the expected completion date of this trial, will be critical factors to watch.